Biosimilars – Market Events And Forecast – Respiratory

In 2019, sales of branded biologics in respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Respiratory
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Respiratory Biologics in Asthma
      • Terminology
      • Overarching Forecast Assumptions
        • Overview of Respiratory Biological Brands in Forecast
          • Overview of Approved Respiratory Biologics in Asthma
          • Biosimilar Entry Assumptions for Biologics in Asthma
        • Overview of Biosimilars in Respiratory Disease Assumptions
        • Drug-Specific Forecast Assumptions
          • Xolair
            • Outlook for Xolair
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Xolair Sales Forecast for the United States (Respiratory): 2019-2029
            • Xolair Sales Forecast for the EU5 (Respiratory): 2019-2029
            • Xolair Sales Forecast for Japan (Respiratory): 2019-2029

      launch Related Market Assessment Reports